Search | IOVS | ARVO Journals

Showing 1 – 20 of 29

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2020

Intraocular pressure (IOP) reduction elicited with NCX 1741, a dual acting nitric oxide (NO) and phosphodiesterase type-5 (PDE5) inhibitor or travoprost in a non-human primate model of ocular hypertension and glaucoma

Francesco Impagnatiello; Tomas Navratil; Carol Toris; Michael V W Bergamini; Stefania Brambilla; Corinna Galli; Nicoletta Almirante; Elena Bastia

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2786. doi:

ARVO Annual Meeting Abstract July 2019

Concomitant dosing of the NO-donor NCX 667 (1%) and Xalatan® (latanoprost ophthalmic solution 0.005%) results in robust and sustained IOP-lowering in ocular normotensive dogs

Michael V W Bergamini; Tomas Navratil; Francesco Impagnatiello; Elena Bastia

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3193. doi:

ARVO Annual Meeting Abstract July 2019

Nonclinical development of NCX 470, a novel nitric oxide (NO)-donating,IOP lowering prostaglandin analog for glaucoma and ocular hypertension

Elena Bastia; Nicoletta Almirante; Michael V W Bergamini; Tomas Navratil; Marlene Woodruff Modi; Francesco Impagnatiello

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3806. doi:

ARVO Annual Meeting Abstract July 2019

Preclinical Evaluation of NCX 4251, a Novel Steroid Therapy for Blepharitis, Targeted Directly to the Eyelid Margin to Reduce the Potential for IOP Elevations

Tomas Navratil; Jean-Michel Bukowski; Frederic Pilotaz; Amanda Graves; Akshay Nadkarni; Amber Allen; Brigitte Duquesroix; Elena Bastia; Laura Storoni; Angela Kothe; Michael V W Bergamini; Jay Pennell; Brian G Short; Thomas Walters; Robert D Fechtner; Donald L Budenz

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6755. doi:

ARVO Annual Meeting Abstract June 2017

Extended release aflibercept with sustained vitreous concentration in non-human primates from biodegradable hydrogel implants

Gary Owens; Melissa Sandahl; Janet Tully; Jennifer Haley; Kwadwo Caesar; Stuart Williams; Rozemarijn S Verhoeven; Andres Garcia; Tomas Navratil; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):409. doi:

ARVO Annual Meeting Abstract June 2017

A 12-Month Study of the ENV515 (Travoprost) Intracameral Implant on Intraocular Pressure in Beagle Dogs

RiLee Robeson; Rozemarijn S Verhoeven; Andres Garcia; Sanjib Das; Kristie Hamby; Melissa Hernandez; Glenwood G Gum; Benjamin R Yerxa; Tomas Navratil

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1072. doi:

ARVO Annual Meeting Abstract June 2017

Extended PGA Delivery Results in Significant Drug Sparing Compared to Topical PGAs and Achieves Sustained IOP Lowering for 11 Months without Any Loss of Efficacy

Tomas Navratil; Jinny Conley; Rozemarijn S Verhoeven; Kristin Blackwell; Akshay Nadkarni; Leo Trevino; Benjamin R Yerxa; Michael Depenbusch; Tracey Knox; Iqbal Ahmad; Thomas R Walters; Steven L Mansberger

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2108. doi:

ARVO Annual Meeting Abstract June 2017

Interim Analysis of Low Dose ENV515 Travoprost XR with 11 Month Duration Followed by Dose Escalation and 28 Day Efficacy Evaluation of High Dose ENV515

Steven L Mansberger; Jinny Conley; Rozemarijn S Verhoeven; Kristin Blackwell; Michael Depenbusch; Tracey Knox; Thomas R Walters; Iqbal Ahmad; Benjamin R Yerxa; Tomas Navratil

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2110. doi:

ARVO Annual Meeting Abstract September 2016

Extended Release of anti-VEGF Biologics from Biodegradable Hydrogel Implants for the Treatment of Age Related Macular Degeneration

Gary Owens; Melissa Sandahl; Melissa Hernandez; Andres Garcia; Stuart Williams; Tomas Navratil; Rhett Schiffman

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):527. doi:

ARVO Annual Meeting Abstract September 2016

Completed 28-Day and Ongoing 12-Month Safety and Efficacy Evaluation of ENV515 (travoprost) Intracameral Implant in Phase 2 Study

Thomas R Walters; Tomas Navratil; Stacey Pittman; Virginia Conley; Leo Trevino; Bruce E Silverstein; Michael Depenbusch; Steven L Mansberger; Rhett Schiffman

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3025. doi:

ARVO Annual Meeting Abstract September 2016

Precision Size and Shape Extended Release Intravitreal Dexamethasone Implants

Sanjib Kiumar Das; Stuart Williams; Janet Tully; Rozemarijn S Verhoeven; Mari Yang; Tomas Navratil; Rhett Schiffman

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3278. doi:

ARVO Annual Meeting Abstract September 2016

A 6-Week Toxicity and Toxicokinetics Study of a Single Bilateral Intracameral Administration of ENV905 (difluprednate) Ophthalmic Implant in New Zealand White Rabbits

RiLee Robeson; Rozemarijn S Verhoeven; Andres Garcia; Paul Miller; Jacqueline Miller; Tomas Navratil; Rhett M Schiffman

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4013. doi:

ARVO Annual Meeting Abstract September 2016

A 6-Week Ocular Pharmacokinetic Study of ENV905 (difluprednate) Intracameral Implant or Durezol in the Albino Rabbit

Rozemarijn S Verhoeven; RiLee Robeson; Andres Garcia; Brian C Gilger; David Culp; Craig B Struble; Lee Hamm; Thomas Grizzle; Tomas Navratil; Rhett M Schiffman

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5711. doi:

ARVO Annual Meeting Abstract September 2016

Design and Development of ENV515 Intraocular Applicator for Intracameral Injections of ENV515 Glaucoma Extended Release (XR) Therapy

Tomas Navratil; Jessie Delgado; Andres Garcia; Gretchen Willard; Andrew Corson; Rozemarijn S Verhoeven; Leo Trevino; Rhett Schiffman

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3021. doi:

ARVO Annual Meeting Abstract June 2015

Advancing ENV515 (travoprost) Intracameral Implant into Clinical Development: Nonclinical Evaluation of ENV515 in Support of First-Time-in-Human Phase 2a Clinical Study

Tomas Navratil; Andres Garcia; Rozemarijn S Verhoeven; Leo Trevino; Brian C Gilger; Steven L Mansberger; Donald L Budenz; Iqbal Ike K. Ahmed; Richard A. Lewis; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5706. doi:

ARVO Annual Meeting Abstract June 2015

Preclinical Evaluation of ENV905 (Difluprednate) Ophthalmic Implant: A Clinical Candidate for the Treatment of Pain and Inflammation Associated with Ocular Surgery

Andres Garcia; Rozemarijn S Verhoeven; Tyler Pegoraro; Jeremy Hansen; Jinny Conley; Rilee Robeson; Brian C Gilger; Tomas Navratil; Benjamin Yerxa

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5897. doi:

ARVO Annual Meeting Abstract June 2015

In-Vitro Release of Bevacizumab from Hydrogel-based Drug Delivery Systems

Janet Tully; Stuart Williams; Kevin Herlihy; Gary Owens; Gabe Fawcett; Nicole Meyer; Tomas Navratil; Benjamin Maynor; Benjamin Yerxa

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):222. doi:

ARVO Annual Meeting Abstract June 2015

EXTENDED RELEASE BEVACIZUMAB INTRAVITREAL IMPLANT IS WELL TOLERATED IN THE AFRICAN GREEN MONKEY

Rozemarijn S Verhoeven; Stuart Williams; Jinny Conley; Gary Owens; Matthew S Lawrence; Tomas Navratil; Benjamin Yerxa

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):230. doi:

ARVO Annual Meeting Abstract June 2015

ESTABLISHING IN VIVO TO IN VITRO CORRELATIONS FOR THE RATE OF RELEASE OF BEVACIZUMAB FROM EXTENDED RELEASE FORMULATIONS

Gary Owens; Stuart Williams; Kevin Herlihy; Janet Tully; Rozemarijn S Verhoeven; Tomas Navratil; Benjamin Maynor; Benjamin Yerxa

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):236. doi:

ARVO Annual Meeting Abstract June 2015

The Aseptic Fabrication of ENV515 (Travoprost) Intracameral Implants

Leo Trevino; Michael Hunter; Sanjib Das; Tyler Pegoraro; Tyler Massey; Andres Garcia; Janet Tully; Kristie Hamby; Tomas Navratil; Benjamin Yerxa

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4158. doi:

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Specify Date Range

Intraocular pressure (IOP) reduction elicited with NCX 1741, a dual acting nitric oxide (NO) and phosphodiesterase type-5 (PDE5) inhibitor or travoprost in a non-human primate model of ocular hypertension and glaucoma

Concomitant dosing of the NO-donor NCX 667 (1%) and Xalatan® (latanoprost ophthalmic solution 0.005%) results in robust and sustained IOP-lowering in ocular normotensive dogs

Nonclinical development of NCX 470, a novel nitric oxide (NO)-donating,IOP lowering prostaglandin analog for glaucoma and ocular hypertension

Preclinical Evaluation of NCX 4251, a Novel Steroid Therapy for Blepharitis, Targeted Directly to the Eyelid Margin to Reduce the Potential for IOP Elevations

Extended release aflibercept with sustained vitreous concentration in non-human primates from biodegradable hydrogel implants

A 12-Month Study of the ENV515 (Travoprost) Intracameral Implant on Intraocular Pressure in Beagle Dogs

Extended PGA Delivery Results in Significant Drug Sparing Compared to Topical PGAs and Achieves Sustained IOP Lowering for 11 Months without Any Loss of Efficacy

Interim Analysis of Low Dose ENV515 Travoprost XR with 11 Month Duration Followed by Dose Escalation and 28 Day Efficacy Evaluation of High Dose ENV515

Extended Release of anti-VEGF Biologics from Biodegradable Hydrogel Implants for the Treatment of Age Related Macular Degeneration

Completed 28-Day and Ongoing 12-Month Safety and Efficacy Evaluation of ENV515 (travoprost) Intracameral Implant in Phase 2 Study

Precision Size and Shape Extended Release Intravitreal Dexamethasone Implants

A 6-Week Toxicity and Toxicokinetics Study of a Single Bilateral Intracameral Administration of ENV905 (difluprednate) Ophthalmic Implant in New Zealand White Rabbits

A 6-Week Ocular Pharmacokinetic Study of ENV905 (difluprednate) Intracameral Implant or Durezol in the Albino Rabbit

Design and Development of ENV515 Intraocular Applicator for Intracameral Injections of ENV515 Glaucoma Extended Release (XR) Therapy

Advancing ENV515 (travoprost) Intracameral Implant into Clinical Development: Nonclinical Evaluation of ENV515 in Support of First-Time-in-Human Phase 2a Clinical Study

Preclinical Evaluation of ENV905 (Difluprednate) Ophthalmic Implant: A Clinical Candidate for the Treatment of Pain and Inflammation Associated with Ocular Surgery

In-Vitro Release of Bevacizumab from Hydrogel-based Drug Delivery Systems

EXTENDED RELEASE BEVACIZUMAB INTRAVITREAL IMPLANT IS WELL TOLERATED IN THE AFRICAN GREEN MONKEY

ESTABLISHING IN VIVO TO IN VITRO CORRELATIONS FOR THE RATE OF RELEASE OF BEVACIZUMAB FROM EXTENDED RELEASE FORMULATIONS

The Aseptic Fabrication of ENV515 (Travoprost) Intracameral Implants

To View More...

You must be signed into an individual account to use this feature.